BH3:FRA
PTC Therapeutics, Inc.
55,34 €
arrow_downward
-1,57%(-0,88) 1D
8 ოქტ, 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
55,34 €
High
55,34 €
Low
55,34 €
Mkt. cap
5,22 მლრდ.
Avg. vol.
0,00
Volume
0,00
52-wk high
77,02 €
52-wk low
52,50 €
No. of employees
991
Open
55,34 €
High
55,34 €
Low
55,34 €
Mkt. cap
5,22 მლრდ.
Avg. vol.
0,00
Volume
0,00
52-wk high
77,02 €
52-wk low
52,50 €
No. of employees
991
News stories
From web sources and news partners
Yahoo Finance
·
17 საათის წინ
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
MarketBeat
·
21 საათის წინ
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock
Investing.com
·
22 საათის წინ
PTC Therapeutics CLO Mark Boulding sells $132,790 in shares
Stock Titan
·
23 საათის წინ
Under a trading plan, PTC Therapeutics (PTCT) CLO sells 1,638 shares, then 435 more.
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOმეთიუ ბი კლეინ
Employees991
Founded1 იან. 1998
HeadquartersWarren, ნიუ-ჯერსი, ამერიკის შეერთებული შტატები
Sector-
Websiteptcbio.com